Skip to content

Circles

Z

ZyVersa Therapeutics, Inc.

ZVSA· OTC

Z

ZVSAZyVersa Therapeutics, Inc.

ZVSAZyVersa Therapeutics, Inc.·Earnings record

Q2 2021

Source filing unavailable

Next · Q3 2021

Q2 2021 · —

Revenue—

Net Income

-$1.90K

no prior Q2 2020 on file

EPS, diluted—

Operating Income-$789—

Operating Cash Flow-$48,075—

Same quarter

no prior Q2 2020 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Filing lag

Quarterly history

Q2 ’21Q3 ’21 Q1 ’22 Q2 ’22 Q3 ’22 Q4 ’22^d Q1 ’23 Q2 ’23 Q3 ’23…

ZyVersa Therapeutics, Inc. · CIK 1859007 · Engraved from SEC EDGAR

Thaler ResearchEngraved from SEC EDGAR© 2026 Thaler. All rights reserved.Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Platform

Using AI API SDKs CLI

Research

News Listen Earnings Insiders Holders Compare Metrics

Screener Watchlists Pies Notes Your companies

Learn

Thaler

Thaler Agent Promise Provenance Circles Account Terms Privacy